Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | PLK1 | P53350 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18821524 | 0.93 | SMN1; SMN2 (0.59) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL250247 | 0.89 | HDAC6 (0.80) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL23933223 | 0.85 | HDAC8 (0.67) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL16198923 | 0.82 | HDAC6 (0.70) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL14115137 | 0.82 | HDAC6 (0.70) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL16709987 | 0.82 | HDAC2 (0.47) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL16501829 | 0.82 | PLK1 (0.47) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL50646 | 0.81 | MAPT (0.68) | HPGDSMN1; SMN2KMT2ALMNAMAPT | |
| SCHEMBL16350551 | 0.80 | HDAC8 (0.52) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 | |
| SCHEMBL2643668 | 0.80 | HDAC8 (0.67) | HDAC2HDAC8HDAC6HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023081328-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-11578438-B2 | Polyamide nanofiber nonwovens for acoustic applications | ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| CN-102007127-A | Furo- and thieno [3,2-c] pyridines | OSI PHARM INC | 2011-04-06 | — | — | CN | disclosed |
| EP-2265616-A1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100256755-A1 | Poly(Tetrafluoroethene) Polymer With Nitric Oxide Donating Surface | MEDTRONIC VASCULAR, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7781570-B2 | Site-specific aminoglycoside derivatives for use in immunodiagnostic assays | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2009100282-A1 | FURO-AND THIENO[3,2-C] PYRIDINES | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20070148700-A1 | SITE-SPECIFIC AMINOGLYCOSIDE DERIVATIVES FOR USE IN IMMUNODIAGNOSTIC ASSAYS | GHOSHAL MITALI | 2007-06-28 | — | — | US | disclosed |
| US-7235370-B2 | antibody produced in response to; effective tool in the guidance is the monitoring of aminoglycoside concentration in the biological fluid of a treated patient | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148700-A1 | SITE-SPECIFIC AMINOGLYCOSIDE DERIVATIVES FOR USE IN IMMUNODIAGNOSTIC ASSAYS | DNPEP, AADAT, ANPEP | HDAC2 3908/4885HDAC8 3387/4885HDAC6 3891/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | HDAC2 4572/4885HDAC8 3632/4885HDAC6 1441/4885 |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | RET, MET, ERBB2 | HDAC2 2324/4885HDAC8 3010/4885HDAC6 2235/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | HDAC2 782/4885HDAC8 816/4885HDAC6 966/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | HDAC2 263/4885HDAC8 95/4885HDAC6 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.